CHERRY HILL, N.J., Sept. 14 Nuvilex, Inc. (OTC Bulletin Board: NVLX) announces today that results from the Company's ongoing sponsored research studies indicate that Oraphyte(TM) can control nematode infestation pre-plant and post-plant in several species of turfgrass. In the coming months Nuvilex intends to initiate trials on golf course greens in the Southeastern United States under conditions that are most optimal for turfgrass growth. These commercial studies will determine and validate Oraphyte's usage requirements and application specifications. Nuvilex plans to register Oraphyte with the Environmental Protection Agency (EPA) in two phases: Nuvilex will first register Oraphyte(TM) with the EPA as a pesticide for use on terrestrial, non-food crops, followed by pesticide registration for use on high-value crops (e.g., terrestrial food crop use) such as soybeans and sugar cane.
From 2007 to 2009, renowned nematologist Edward McGawley, Ph.D. of the Louisiana State University Agricultural Center (LSU AgCenter) has investigated the use of Oraphyte(TM) as an all-natural nematocide for turfgrass. Initial greenhouse and Phase 1 microplot experiments conducted in 2007 and 2008 demonstrated that Oraphyte(TM) could control populations of nematodes in turfgrass; however, early formulations appeared to be phytotoxic.
From May to August 2009, Phase 2 microplot experiments conducted at the LSU AgCenter included the application of a new and improved Oraphyte(TM) formula to six nematode genera that were added to the soil of Agrostis stolonifera (Penn G2 Bentgrass) and Cynodon (Bermudagrass). Both species of turfgrass were grown in microplots in a controlled environment. Each microplot contained approximately 15-35 kg of soil and approximately 1.7 ft2 of turfgrass. Preliminary results showed that the new and improved formulations caused a statistically significant reduction in the number of nematodes that remained in the soil upon the completion of the experiment. In addition, Oraphyte(TM), as determined by measuring the mean cumulative turfgrass clipping weights, does not appear to be phytotoxic to turfgrass. The cumulative grass clipping weights of microplots that received Oraphyte(TM) were not statistically different from the controls that received no pesticide and no nematodes. The final report on the LSU Phase 2 microplot trials will be issued on or before October 31, 2009.
"The transition from laboratory to commercial testing for Oraphyte(TM) is a very important step in the product's evolution to market launch," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "The demand for an all-natural, eco-friendly nematocide amongst golf course superintendents and farmers continues to increase as the number of EPA-registered synthetic nematocides decreases. We anticipate, with continuing positive test results, that the market acceptance of Oraphyte(TM) as a major product in the new eco-friendly pesticide market will be strong."
Oraphyte(TM) is an all-natural, eco-friendly, biodegradable nematocide for turfgrass and high-value crops. Oraphyte(TM) can be formulated as a liquid or solid and is composed of orange terpene oil, Valencia orange oil, hydrogen peroxide, sorbitan monooleate, and distilled water. All of Oraphyte's ingredients are listed on the Office of Prevention, Pesticides, and Toxic Substances (OPPTS) of the United States Environmental Protection Agency's (EPA) inert ingredient list.
From 2007 to 2009, Oraphyte has undergone testing at Louisiana State University, Auburn University, the University of Florida, Ohio State University, and the USDA to determine its efficacy and usefulness as a non-toxic, low-cost alternative to many traditional nematocides, including Nemacur, Curfew, Telone II, and Temik.
About Nuvilex, Inc.
Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.
Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., the Company's ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Company Contact: Blair Barnes Senior Vice President and Chief Financial Officer Nuvilex, Inc. Ph: 856-433-6088 Email: firstname.lastname@example.org Press Contact: Pat Arcand Arcand & Madison Ph: 617-576-7777 Email: email@example.com
SOURCE Nuvilex, Inc.